Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

Long-term Safety of TPN171H Tablet in Erectile Dysfunction.

A legfontosabb adatok

Ki végzi
Vigonvita Life Sciences
Hol
Kína34 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
472 fő vett részt
Kezdés
2024. ápr. 12.
Befejezés
2025. jún. 5.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • TPN171H
A regiszteradat frissítve
2025. július 25.

Ki vehet részt

Életkor
18 év – 75 év
Nem
Csak férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 30 feltétel megnézéseKevesebb

Ki vehet részt

  • 18 years to 75 years (inclusive)
  • Males with ED at least 3 months
  • IIEF-5 ≤ 21 at visit 1
  • Patients in a stable, heterosexual relationship during the study
  • At the end of the untreated baseline period, the following conditions are met:(1)The subject must make at least four attempts at sexual intercourse during the untreated baseline period. (2)At least 50% of attempts during this period must be unsuccessful,(unsuccess means at least one of the first three questions should be answered "No" in SEP).(3)5≤IIEF-EF≤25
  • Patients who are willing to have 4 or more attempts of sexual intercourse per month, demonstrated compliance with the study protocol, including drug administration, diary completion, and scheduled study visits, during the qualifying trial
  • Patients who are willing to take proper contraceptive during the study and within 3 months after the last dose
  • Patients who have voluntarily decided to participate in this study, and signed the informed consent form

Ki nem vehet részt

  • Patients with ED, which is caused by spinal injury or have had a radical prostatectomy or other surgery
  • Patients who have a penile implant
  • Patients who do not respond to marketed PDE5 inhibitors or have adverse reactions that lead to drug discontinuation
  • CYP3A4 potent inhibitors, moderate inhibitors, and potent inducers need to be used during the trial or discontinued for less than 31 days before enrollment
  • Subjects who are taking nitrate or NO donor drugs, guanylate cyclase agonists and cannot be discontinued during the trial
  • Patients who have used other drugs in clinical trials within the last 1 month
  • Patients who have a history of hypersensitivity to other PDE5 inhibitors or TPN171H
  • Patients with ED, which is caused by any other primary sexual disorder
  • Patients with the following cardiovascular disease: Myocardial infarction or stroke within the last 6 months; Unstable angina or angina occurring during sexual intercourse; New York Heart Association Class 2 or greater heart failure in the last 6 months
  • Uncontrolled hypotension (<90/60mmHg) or uncontrolled hypertension (≥180/110mmHg)
  • Patients with active gastrointestinal ulcers and bleeding disorders
  • Patients who have a history of NAION, or with a known genetically degenerative retinopathy, including retinitis pigmentosa
  • Patients who have a history of sudden decrease or loss of hearing
  • Patients with a history of severe central nervous system injury or peripheral muscular neurological disease in the past 6 months
  • Patient with a history of malignancy
  • Patients whose partner is breastfeeding/pregnant/trying to become pregnant, has a gynecological disease or is restricted in their activities during treatment
  • Patients with hepatic or renal dysfunction as per the following: AST, ALT>3*ULN, serum creatinine exceeds 50% of the upper limit of normal value
  • Patients with anatomical malformations of the penis
  • Patients with primary hypoactive sexual desire
  • Patients with diabetic complications (diabetic nephropathy, peripheral neuropathy)
  • Patients with significant neurological abnormalities who are unable or unwilling to cooperate
  • For other reasons besides the aforementioned cases, patient whose participation is deemed inappropriate

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a multicenter, open study to evaluate the long-term safety and efficacy of TPN171H in men with erectile dysfunction.

A vizsgálat csoportja

  • TPN171H groupA vizsgált kezelés

    10 mg/ time, as needed, it is recommended to take warm water within 0.5 to 4 hours before sexual activity.

    Kezelés: TPN171H

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Multicenter, Open Study to Evaluate the Long-term Safety and Efficacy of TPN171H in Patients With Erectile Dysfunction
A regiszteradat frissítve
2025. július 25.